[go: up one dir, main page]

IS8293A - Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX - Google Patents

Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX

Info

Publication number
IS8293A
IS8293A IS8293A IS8293A IS8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A
Authority
IS
Iceland
Prior art keywords
pyrrole
dione derivatives
liver receptor
regulate liver
regulate
Prior art date
Application number
IS8293A
Other languages
English (en)
Inventor
Boström Jonas
Brickmann Kay
Holm Patrik
Sandberg Pernilla
Swanson Marianne
Westerlund Christer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8293A publication Critical patent/IS8293A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8293A 2003-07-11 2006-02-09 Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX IS8293A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001114 WO2005005417A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
IS8293A true IS8293A (is) 2006-02-09

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8293A IS8293A (is) 2003-07-11 2006-02-09 Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX

Country Status (26)

Country Link
US (1) US7432288B2 (is)
EP (1) EP1646626B1 (is)
JP (1) JP2007521312A (is)
KR (1) KR20060035748A (is)
CN (1) CN1823061A (is)
AR (1) AR045721A1 (is)
AT (1) ATE399777T1 (is)
AU (1) AU2004255999B2 (is)
BR (1) BRPI0412472A (is)
CA (1) CA2532056A1 (is)
DE (1) DE602004014773D1 (is)
ES (1) ES2308204T3 (is)
GB (1) GB0316232D0 (is)
HK (1) HK1088320A1 (is)
IL (1) IL172760A0 (is)
IS (1) IS8293A (is)
MX (1) MXPA06000414A (is)
MY (1) MY135821A (is)
NO (1) NO20060081L (is)
RU (1) RU2006102130A (is)
SA (1) SA04250204B1 (is)
TW (1) TW200503691A (is)
UA (1) UA82109C2 (is)
UY (1) UY28408A1 (is)
WO (1) WO2005005417A1 (is)
ZA (1) ZA200600222B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
EP1838686A4 (en) 2005-01-10 2010-02-24 Astrazeneca Ab ISOTHIAZOL-3 (2H) -ONE 1,1-DIOXIDE DERIVATIVES AS LIVER X-RECEPTOR MODULATORS
EP2029536B1 (en) * 2006-04-28 2013-08-28 Laboratorios Del. Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
AU2007286807B2 (en) 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
CA2727252A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
AU2009266956B2 (en) 2008-07-01 2014-03-20 Genentech, Inc. Bicyclic heterocycles as MEK kinase inhibitors
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
EP2646018B1 (en) 2010-12-03 2014-10-22 Allergan, Inc. Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
KR20130127479A (ko) 2010-12-03 2013-11-22 알러간, 인코포레이티드 스핑고신 1-포스페이트 (s1p) 수용체 조절제로서의 신규한 옥심 유도체
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
WO2017123568A2 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
WO2022109066A1 (en) * 2020-11-18 2022-05-27 Southern Research Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27510A (id) 1998-07-30 2001-04-12 Japan Tobacco Inc Senyawa malimida tersubstitusi dan penggunaan farmasinya
EP1119548B1 (en) * 1998-10-08 2004-12-08 SmithKline Beecham plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク インコーポレイテッド Hdlコレステロール値を上昇させる組成物および方法
WO2001013916A1 (fr) 1999-08-20 2001-03-01 Sagami Chemical Research Center Medicaments inhibant la mort cellulaire
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
AU2004255999B2 (en) 2007-08-02
HK1088320A1 (en) 2006-11-03
EP1646626A1 (en) 2006-04-19
MY135821A (en) 2008-07-31
TW200503691A (en) 2005-02-01
NO20060081L (no) 2006-02-08
CA2532056A1 (en) 2005-01-20
GB0316232D0 (en) 2003-08-13
KR20060035748A (ko) 2006-04-26
ZA200600222B (en) 2007-04-25
CN1823061A (zh) 2006-08-23
SA04250204B1 (ar) 2008-03-23
ATE399777T1 (de) 2008-07-15
UA82109C2 (uk) 2008-03-11
AU2004255999A1 (en) 2005-01-20
WO2005005417A1 (en) 2005-01-20
BRPI0412472A (pt) 2006-09-19
JP2007521312A (ja) 2007-08-02
US7432288B2 (en) 2008-10-07
DE602004014773D1 (de) 2008-08-14
UY28408A1 (es) 2005-02-28
US20060235015A1 (en) 2006-10-19
IL172760A0 (en) 2006-04-10
RU2006102130A (ru) 2007-08-20
MXPA06000414A (es) 2006-03-17
ES2308204T3 (es) 2008-12-01
AR045721A1 (es) 2005-11-09
EP1646626B1 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
IS8293A (is) Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX
IS8291A (is) Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
IS8466A (is) 3-Sýklóalkýlamínópýrrólidín afleiður sem stillar á flakkboða viðtaka
HK1209729A1 (en) Compounds, compositions and methods
HK1090635A1 (en) Substituted 3-sulfur indoles
ZA200702479B (en) 4-heteroarylmethyl substituted phthalazinone derivatives
IL181408A0 (en) 4-heteroarylmethyl substituted phthalazinone derivatives
ATE440085T1 (de) 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
DK1824856T3 (da) 2,4 (4,6)-pyrimidinderivater
ZA200700159B (en) Phenyl substituted [1.2]-oxazine-3,5-dione and dihydropyrone derivatives
IL183594A0 (en) Phenyl-piperazin methanone derivatives
DE502005007723D1 (de) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone,
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
EP1811842A4 (en) IMMUNE ACTIVATION COMPOSITIONS BASED ON 3,3'-DIINDOLYLMETHANE
BRPI0509256A (pt) derivados de pirrolidina-3,4-dicarboxamida
DE502005000496D1 (de) Verstellvorrichtung
ES1058958Y (es) Mastil perfeccionado.
EP1711189A4 (en) AZALIDE DERIVATIVES 8A 6,11-3C-BICYCLIC
ES1058483Y (es) Bloque de asientos perfeccionado.
ES1057238Y (es) Buzon perfeccionado.
ITRM20040370A1 (it) Chiusino perfezionato.
GB0413742D0 (en) Cross-cut router attachment
ES1058233Y (es) Cambrillon perfeccionado.
ES1057931Y (es) Sacacorchos de palanca perfeccionado.